Mometazonfuroat Cipla (Mometasone Furoate)

Mometasone furoate binds to glucocorticoid receptors in the cells lining the nasal mucosa. This interaction modifies gene expression, leading to reduced production of inflammatory cytokines and chemokines. The resulting anti‑inflammatory effect diminishes swelling and mucus production, improving nasal airflow.

The specific dose and frequency of Mometazonfuroat Cipla are determined by the prescribing healthcare professional based on the patient’s age, severity of symptoms, and clinical response. Patients should follow the prescriber’s instructions and the product’s label for proper administration.

Safety data for mometasone furoate nasal spray in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using the product.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Mometazonfuroat Cipla contains mometasone furoate, which is a high‑potency, once‑daily nasal corticosteroid. Compared with older agents such as fluticasone or budesonide, mometasone often provides comparable or greater symptom control at lower doses, with a similar safety profile when used as directed.

The nasal spray should be stored at room temperature, preferably below 25 °C. Keep the device in its original packaging, protect it from moisture and direct sunlight, and ensure the cap is tightly closed when not in use.

Mometazonfuroat Cipla is administered as a nasal spray. The patient should gently blow the nose, tilt the head slightly forward, insert the nozzle into one nostril, and spray the prescribed number of sprays while breathing in gently. The same procedure is repeated in the other nostril if required.

Serious but rare risks include nasal septal perforation, severe allergic reactions such as anaphylaxis, vision changes (including cataracts or glaucoma), and systemic adrenal suppression with prolonged high‑dose use. Any signs of these conditions should prompt immediate medical evaluation.

Patients with known hypersensitivity to mometasone furoate or any component of the formulation should avoid using the spray. Additionally, individuals with active untreated fungal, viral, or bacterial infections of the nasal passages should not use it until the infection is resolved.